BetterLife Pharma (BETR) AI Stock Analysis

• Market Cap: C$7.59M
• Dividend Yield: N/A
• Average Volume (3M): 121.96K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.34
• Revenue Growth: N/A
• EPS Growth: 62.43%
• Country: CA
• Employees: 4
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 151,896,680
• 10 Day Avg. Volume: 118,740
• 30 Day Avg. Volume: 121,961
• PEG Ratio: -0.60
• Price to Book (P/B): -1.51
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -7.96
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: C$0.04 ▲(7.50% Upside)

The score is held down primarily by weak financial fundamentals (no revenue, ongoing losses, and negative equity) and bearish technical trend signals. Improving TTM cash burn and a set of positive corporate updates provide some support, but valuation remains constrained by unprofitability and lack of dividend.

BetterLife Pharma Business Overview & Revenue Model

Company Description

BetterLife Pharma Inc., a biotechnology company, engages in the development and commercialization of compounds for the treatment of neurological disorders in Canada and internationally. It is involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections. The company's pipeline products include BETR-001 for the treatment of major depressive disorder, treatment resistance depression, cluster headaches, and post-traumatic stress disorder; and BETR-002 to treat benzodiazepine dependency, anxiety, and spasticity. It is also developing MM-003 for treatment of COVID-19 and other respiratory viral infections; MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia; and AP-002 for the treatment of cancer. BetterLife Pharma Inc. has a research agreement with the University of California San Diego for preclinical behavioral pharmacology studies of TD-0148A, a lysergic acid diethylamide derivative solution. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.

How the Company Makes Money

BetterLife Pharma makes money primarily through the development and commercialization of its therapeutic products. The company's revenue model is based on the successful advancement of its drug candidates through clinical trials and obtaining regulatory approvals, which can lead to partnerships or licensing agreements with larger pharmaceutical companies. Additionally, as these therapies reach the market, BetterLife Pharma could generate revenue through direct sales or royalties from licensing agreements. Investment from venture capital or strategic partners also plays a significant role in funding the company's research and development activities, which indirectly contributes to its financial sustainability.

BetterLife Pharma Financial Statement Overview

Summary

BetterLife Pharma is facing severe financial challenges with no revenue generation, substantial losses, negative equity, and unsustainable cash flows. The company's financial health is weak, with high leverage and dependency on financing activities to maintain liquidity.

Income Statement

BetterLife Pharma has not generated any revenue over the past years, leading to negative gross profit and net income. The company shows significant losses, with high negative EBIT and EBITDA margins. The absence of revenue growth and persistent losses highlight financial challenges.

Balance Sheet

The company has negative stockholders' equity, indicating liabilities exceed assets, which is a significant financial concern. The debt-to-equity ratio cannot be computed due to negative equity, but substantial debt levels pose a high leverage risk. The financial structure is unstable, with liabilities consistently rising.

Cash Flow

Operating cash flows are negative, reflecting cash outflows from operations. Free cash flow is also negative, indicating financial strain in sustaining operations. The financing activities seem to be the primary source of liquidity, but the overall cash flow position is unsustainable.

Breakdown	Dec 2025	Dec 2024	Dec 2022	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	-18.44K	-18.43K	―
EBITDA	0.00	-3.19M	-11.92M	-9.24M	-7.61M
Net Income	-3.52M	-2.89M	-12.16M	-9.02M	-36.35M
Balance Sheet
Total Assets	224.96K	324.75K	1.16M	74.73K	1.34M
Cash, Cash Equivalents and Short-Term Investments	8.18K	37.38K	173.51K	8.31K	154.72K
Total Debt	1.30M	1.47M	1.40M	1.19M	500.00K
Total Liabilities	7.59M	8.02M	5.04M	7.61M	5.95M
Stockholders Equity	-10.68M	-10.81M	-3.88M	-10.73M	-4.61M
Cash Flow
Free Cash Flow	-2.02M	-2.47M	-11.20M	-1.50M	-7.26M
Operating Cash Flow	-2.02M	-2.47M	-11.20M	-1.50M	-7.16M
Investing Cash Flow	0.00	0.00	―	165.04K	-71.55K
Financing Cash Flow	1.99M	2.50M	11.23M	1.34M	4.09M

BetterLife Pharma Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.04
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BETR, the sentiment is Neutral. The current price of 0.04 is below the 20-day moving average (MA) of 0.05, below the 50-day MA of 0.06, and below the 200-day MA of 0.08, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 48.72 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:BETR.

BetterLife Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MDMA	49 Neutral	C$13.07M	-5.97	-85.96%	―	-72.51%	-170.13%
MOOD	47 Neutral	C$4.81M	-5.96	-41.36%	―	-50.89%	-32.33%
PHRM	45 Neutral	C$9.10M	-5.62	-112.32%	―	―	27.35%
BETR	43 Neutral	C$7.59M	-3.76	―	―	―	62.43%
MRVL	42 Neutral	C$8.12M	-3.11	―	―	―	―

BetterLife Pharma Corporate Events

BetterLife Pharma Targets Global Partners for BETR-001 at JPM Week Forums

BetterLife Pharma said it will participate in the YAFO Capital Access Asia 2025 Partnering Forum during JPM Week in San Francisco, positioning the company to meet investors, pharmaceutical partners and strategic advisors from North America and Asia as it advances its flagship neurological drug candidate BETR-001. Chief executive Dr. Ahmad Doroudian will also attend a slate of high-profile industry gatherings, including the H7 Life Science Investment Forum, WuXi Global Forum 2026 and the DARPA and Ferocity Capital Biodefence Summit, where he will hold one-on-one meetings to discuss BetterLife’s development strategy for BETR-001, potentially broadening the company’s financing options, partnership prospects and visibility in the global life sciences and biodefence ecosystems.

The most recent analyst rating on (TSE:BETR) stock is a Hold with a C$0.04 price target. To see the full list of analyst forecasts on BetterLife Pharma stock, see the TSE:BETR Stock Forecast page.

BetterLife Pharma Director and Audit Chair Robert Metcalfe Resigns

BetterLife Pharma Inc. has announced the resignation of Robert Metcalfe from its board of directors, where he served for six years and chaired the audit committee, marking a notable change in the company’s governance structure. Chief executive Ahmad Doroudian thanked Metcalfe for his long-standing service and said the company will begin searching for new director candidates as it advances its development plans, a move that could influence oversight and strategic direction as the biotech pursues its neurological and antiviral drug pipeline.

BetterLife Pharma Partners with YAFO Capital for BETR-001 Expansion in Greater China

BetterLife Pharma has engaged Shanghai-based YAFO Capital as its exclusive advisor to seek strategic partnerships for the development of its proprietary BETR-001 in the Greater China regions. This collaboration aims to leverage YAFO’s expertise and network to accelerate the development and strategic partnering opportunities for BETR-001, a non-hallucinogenic treatment for neurological disorders, in Asia.

BetterLife Pharma Advances BETR-001 as a Non-Hallucinogenic Neuroplastogen

BetterLife Pharma has highlighted the advantages of its proprietary compound BETR-001, which remains non-hallucinogenic even at high doses, unlike traditional LSD microdosing. The company plans to file an IND and begin human clinical trials by the second half of 2026, targeting conditions such as traumatic brain injury, cluster headaches, and migraines. BETR-001’s ability to be administered at full doses without hallucinations positions it as a promising treatment for a range of psychiatric disorders, potentially enhancing BetterLife’s market position in the biotech industry.

BetterLife Pharma Appoints Daniel Carcillo as Corporate Advisor

BetterLife Pharma has appointed Daniel Carcillo, a former NHL player and advocate for traumatic brain injury (TBI) survivors, as a Corporate Advisor to advance the development of BETR-001, focusing on TBI, cluster headaches, and migraines. Carcillo’s personal experience with brain trauma and his advocacy work are expected to provide valuable insights, potentially enhancing the company’s position in the biotech industry and offering hope to stakeholders seeking innovative treatments for neurological disorders.

BetterLife Pharma Announces Debt Conversion and Board Resignation

BetterLife Pharma Inc. has announced the issuance of 57,945 common shares and share purchase warrants as part of a debt conversion related to accrued interest on convertible debentures. The company also reported the resignation of Mr. André Beaudry from its Board of Directors and plans to appoint new corporate advisors soon. These developments are part of BetterLife’s ongoing efforts to strengthen its financial position and governance as it continues to focus on its core projects in neurological disorder treatments.

BetterLife Pharma Appoints Doug Drysdale as Corporate Advisor to Advance Neurological Treatments

BetterLife Pharma has appointed Doug Drysdale as Corporate Advisor to advance its product BETR-001 for non-psychiatric indications, focusing on cluster headache and migraine. Drysdale’s extensive experience in leading biotech companies and successful transactions is expected to bolster BetterLife’s efforts in developing BETR-001, a patented stereoisomer of 2-bromo-LSD, which has shown promise in reducing cluster headache frequency. This strategic move aims to enhance BetterLife’s position in the biotechnology industry and potentially impact stakeholders positively by advancing innovative treatments for neurological disorders.